{"id":231640,"date":"2025-10-02T12:22:15","date_gmt":"2025-10-02T16:22:15","guid":{"rendered":"https:\/\/ibkrcampus.com\/campus\/?p=231640"},"modified":"2025-10-02T12:29:13","modified_gmt":"2025-10-02T16:29:13","slug":"is-the-fountain-of-youth-finally-open-for-business","status":"publish","type":"post","link":"https:\/\/www.interactivebrokers.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/","title":{"rendered":"Is the Fountain of Youth Finally Open for Business?"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">From CRISPR breakthroughs to AI-powered drug discovery, longevity science is moving from myth to marketplace. Host <strong>Andrew Wilkinson<\/strong> sits down with <strong>Alex Gunz<\/strong>, Portfolio Manager at Heptagon Capital, to explore how innovations in genomics, stem cells, and personalized medicine could redefine healthcare \u2014 and reshape the investment landscape. Discover why the race to extend lifespan may also unlock new long-term returns.<\/p>\n\n\n\n<iframe title=\"Is the Fountain of Youth Finally Open for Business?\" allowtransparency=\"true\" height=\"150\" width=\"100%\" style=\"border: none; min-width: min(100%, 430px);height:150px;\" scrolling=\"no\" data-name=\"pb-iframe-player\" src=\"https:\/\/www.podbean.com\/player-v2\/?i=ds5qt-1980dc0-pb&#038;from=pb6admin&#038;share=1&#038;download=1&#038;rtl=0&#038;fonts=Arial&#038;skin=1b1b1b&#038;font-color=ffffff&#038;logo_link=episode_page&#038;btn-skin=c73a3a\" loading=\"lazy\"><\/iframe>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-summary-ibkr-podcasts-ep-302\">Summary \u2013 IBKR Podcasts Ep. 302<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><em>The following is a summary of a live audio recording and may contain errors in spelling or grammar. Although IBKR has edited for clarity no material changes have been made<\/em>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Welcome to this episode of IBKR Podcast. Today, we&#8217;re gonna dive into the life science that addresses longevity. With me to explain is <strong>Alex Gunz<\/strong>, who is the Portfolio Manager at Heptagon Capital over in London. Welcome back to the program, Alex.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Always a pleasure to be here, Andrew.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-0\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Let&#8217;s dive straight in. Can you explain why longevity science represents such a significant shift in how we are approaching healthcare, moving from treating diseases to optimizing health?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-0\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This is such an exciting and broad topic, Andrew. It&#8217;s something we&#8217;ve been writing about for six years, and I guess I&#8217;d refer everyone to Benjamin Franklin, who talked very famously about how the only two things that were certain in life were death and taxation. So there\u2019s no doubt we\u2019re getting older \u2014 we\u2019re all getting older.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This is a massive challenge for the planet, and therefore it behooves everyone to come up with solutions. And I think the good news, anyway, is that there is a huge amount of capital being thrown at this. And really, there are two key things I would call out. Number one is that there is occurring, at the moment we feel, a really clear paradigm shift where medicine and healthcare are really moving from being reactive to preemptive. That&#8217;s going to really change the equation.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">And number two, nearly all of the thought process that\u2019s occurring at the exciting edge of this really treats the human body in a somewhat novel way. We think almost of the human body now as being just like any other bit of hardware. In other words, it\u2019s something to be hacked, to be optimized and upgraded \u2014 and therein lies the potential.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-1\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">So how do you define the distinction between lifespan and healthspan, and why is that differentiation crucial for understanding longevity science, Alex?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-1\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">It is absolutely crucial, Andrew. And I guess the easiest way to explain it is by posing the following question: Why would you want to live a longer life if it weren\u2019t a healthier one?&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In other words, there is no point in spending your remaining years on this planet \u2014 or anyone spending their remaining years on this planet \u2014 in ill health if they\u2019re not going to enjoy that time alive. So put very simply, lifespan is the number of years that anyone will live, whereas healthspan is the number of years that anyone will live healthily. And what we\u2019re seeing in almost every developed country around the world is that the gap between the two is widening. And therefore, it\u2019s up to the science and the investment to try and narrow that gap.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-2\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">How has our understanding of aging changed with advances in genomics and regenerative medicine?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-2\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">I think it\u2019s best to really frame the answer to this question in the following way. Big picture \u2014 there are so many different innovations going on within the space of longevity. There are multiple overlapping experiments, moonshots \u2014 not all of them are mutually exclusive.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">But I think, to pick up on the point or the question you asked, Andrew, I\u2019d highlight that clearly, as all your listeners should know, the cost of DNA sequencing and of identifying little bits, if you will, of our genome \u2014 the different parts of our DNA \u2014 has come down massively. And as a result, it effectively means you have a much bigger dataset with which to play.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">And we actually understand how our genes \u2014 how our DNA \u2014 is changing. Then, the ability to try and address those changes only goes up proportionately.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-3\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">How about CRISPR technology? How is that technology being applied to longevity research, and what breakthroughs are we seeing?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-3\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">We\u2019ve been massive fans of CRISPR, Andrew, for quite some time. We first discussed this in one of our thematic pieces, I believe, back in 2017.Perhaps not all of your listeners will be familiar with CRISPR. For those who are not, it\u2019s an acronym for <em>Clustered Regularly Interspaced Palindromic Repeats<\/em> \u2014 obviously a bit of a mouthful, hence why it\u2019s called CRISPR. And the way we try and characterize it is simply: if you think about the tools, if you will, that exist within your word-processing office suite \u2014 i.e. the ability to find and replace, to cut, copy, and paste \u2014 this is effectively what CRISPR allows you to do with DNA.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In other words, you are \u2014 and perhaps to preempt another topic we may discuss, Andrew \u2014 you\u2019re moving increasingly with something like CRISPR, with that combination of understanding our DNA much better, almost to a situation where you can get more and more personalized medical outcomes. There\u2019s also a huge swathe of very rare diseases that CRISPR can potentially address, too.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-4\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">And then what about artificial intelligence, Alex \u2014 what role is that playing in advancing longevity science?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-4\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">I think there are probably two key things I\u2019d call out in this respect.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The first is almost a meta observation. We\u2019ve been discussing artificial intelligence for years now \u2014 right? Since 2016, long before ChatGPT and DeepSeek came along. And really, the basic point is that artificial intelligence for many years was called \u201cbig data.\u201d It was called \u201cmachine learning.\u201d Often, these terms are confused and conflated anyway. So, put very simply, if you now have a bigger dataset \u2014 whether it\u2019s a dataset of DNA, whether it\u2019s a dataset of a population, whether it\u2019s a dataset of eating habits \u2014 and you can actually apply analysis, you can make predictions, then you will likely get to better outcomes.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">We\u2019ve consistently argued that technology \u2014 whether it\u2019s something perceived old-fashioned like cloud, or something much more sort of front-of-mind today like AI \u2014 these are means to an end. They are enablers, and they should help us solve problems \u2014 major meta problems, big-picture thematic problems like aging, improving longevity \u2014 more efficiently. That\u2019s the meta thesis. Quite specifically \u2014 I apologize, I don\u2019t have these figures off the top of my head, but they\u2019re very well known and well documented \u2014 and these relate to the amount of time and money that it takes to bring any drug from inception, idea within a laboratory if you will, through Phase 1, Phase 2, Phase 3 trials, to commercial launch.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I think you\u2019re talking often of maybe a 10-year time horizon, a cost of say a billion dollars, and maybe a 10% success rate. So put very simply, how do you improve those metrics or those ratios? Don\u2019t quote me on those figures, but I think your listeners should understand the broad challenge. And if AI as a tool basically allows you to minimize or reduce that risk of failure, then surely it\u2019s got to be a good thing in this broader debate about longevity.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-5\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Now, what about personalized medicine \u2014 what role is that playing in longevity science?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-5\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">We touched a little bit on this earlier, Andrew, and I think it is almost the ultimate endgame in the sense that, if you take a step back and you think about how all of us \u2014 you, me, every single person listening to this \u2014 what we are made up of, our DNA is something like 99.99% identical.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">But it\u2019s that tiny little bit that is not identical where you have those variances \u2014 and why two people who may live next door to each other, may be exactly the same age, have the same lifestyle habits, that one of them is gonna live 10 years longer than the other. And if you think about it at that \u2014 at our core, if you will \u2014 our DNA, our stem cells, these are almost effectively the toolkit, if you will, for how to have\u2026 I should rephrase that \u2014 for how to have a longer life. So if, with a combination of big data, advances in science, and actually that ability to move to a much more personalized approach to medicine, we can lead better lives, then potentially we will.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I\u2019ll just make one other side observation. When we spoke on a prior call like this, Andrew, we discussed space and the opportunity for the commercialization of space. I was actually on a panel yesterday at an event \u2014 listening to a panel at an event yesterday \u2014 and they made a very good case for upside within space, with one of the scenarios or use cases being that stem cells will actually grow more effectively in a zero-gravity environment. So as the barriers to putting things into space fall, the scope for stem cell growth \u2014 or the expansion of the stem cell industry, if you will \u2014 and its application to longevity should, in my mind, our minds, only go up.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-6\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Now, I think in your recent paper \u2014 available on your website and on Traders\u2019 Insight too \u2014 over $8 billion has been invested in longevity science last year, 2024. What areas are seeing the most promising development, Alex?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-6\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">That $8 billion is a wonderful headline figure, and before we get too excited about it \u2014 not to trivialize it at all \u2014 a lot of it has gone into some very high-profile areas, Andrew. And I think almost what\u2019s occurring now is that, historically, if you were a wealthy billionaire, you\u2019d made your money, say, in old-fashioned media, then you might buy a sports club or something like that. What seems to be occurring now, particularly for many of the uber-successful people \u2014 whose names will all be familiar to us in Silicon Valley \u2014 they\u2019ve not only made their billions, now they want to live longer as well, and therefore they\u2019re throwing a lot of dollars at moonshots.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">And some of the headline-grabbing things relate, say, to brain-computer interfaces, to cryogenics \u2014 high freezing your body \u2014 to uploading your memories, if you will, into some sort of cloud so that they\u2019ll be available for future generations. And I think it\u2019s always been the case, as we all know, that some people like headline-catching, eye-catching ideas. So that\u2019s where a lot of the money, in reality, is going.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If you were asking the question, \u201cWhich of those dollars is really adding value?\u201d I think the more exciting areas are probably the ones that are harder to commercialize. I think everyone will be aware that, under the current administration, funding to many universities and research laboratories is being restrained. Clearly, the process for getting regulatory approval for drugs has always been complicated. And given that context, the easier dollars \u2014 the more compelling money, if you will \u2014 is going into those shorter-term, easier wins.\u00a0So it\u2019s either the less regulated areas like food and nutraceuticals \u2014 that we haven\u2019t talked about so much so far \u2014 or it\u2019s those more eye-catching moonshots backed by famous people, like brain-computer interfaces.\u00a0<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-7\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">What\u2019s the timeline on all of this, Alex? How will the practical application of longevity science reach mainstream healthcare? How long do you think that will take?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-7\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">I think the framing context for this, Andrew, is really to return to the idea that there are multiple, sometimes overlapping projects underway. So there are obviously, today, easy wins.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In other words, you can walk into any pharmacy or large supermarket health store \u2014 either in the United Kingdom or the United States, or indeed many other places in the world \u2014 and there will be whole shelves of products promoting better health and, by implication, longer life. So some of that is available today, clearly.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Medicine \u2014 and it\u2019s a bit like a supertanker \u2014 these things do not turn around overnight. But we said the paradigm is slowly, in our opinion, but surely shifting from reaction to preemption. A visit to your doctor, the amount of information that\u2019s available online, will actually really say, \u201cYou should do X, Y, and Z today in order to lead a longer life.\u201d And things like wearables \u2014 even your iPhone \u2014 that will allow you to monitor your steps, to record your heart rate, whatever it might be, these things could all be considered part of the longevity megatrend.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">If you\u2019re asking the question, \u201cWhen are stem cell solutions, when is personalized DNA, when is CRISPR going to become mainstream?\u201d \u2014 my best guess is, or hope anyway, somewhere before the end of this decade. If you\u2019re asking about when things like brain-computer interfaces will become more widespread, more mainstream almost, I\u2019d say that\u2019s much longer term.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-8\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Now, any MBA student would ask you, Alex \u2014 as this technology has been developed, what are the ethical challenges? What considerations should be thought about?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-8\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">I think there are absolutely no shortage of ethical challenges, and this again makes the whole debate a bit more complicated. It also adds confusion to your question about when these things become mainstream. I guess almost the starting point is that if you believe in natural selection, you believe in DNA, then we as humans are on this planet only for a finite period of time. Our purpose is not to live forever. Our purpose \u2014 our bodies are coded, if you will \u2014 to reproduce, and that\u2019s it.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The reality also is that we don\u2019t quite understand today how and why we age. Ultimately, the likelihood is something will get us in the end. When you think about the ethical issues, then we get into debates about who should have access to these solutions. How much will they cost? There is also the debate about intergenerational equity. If people live for longer, how do we ensure that new people being born get allocation?&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">And what I mean by allocation is not just resource from older generations living longer, but ultimately \u2014 and almost this is the key discussion we come back to time and time again when we talk about future trends \u2014 is, look, we need to come up with solutions about how to allocate scarce resources to a growing population. And if the population\u2019s expanding, then there is the challenge about how you allocate that scarce resource.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">And then I guess the very final point is, look, the whole world has only improved, in my opinion, as a result of innovation. And innovation is simply a function of new people \u2014 generally younger people \u2014 coming to the table, bringing new, exciting ideas to the planet. And if we\u2019ve got more people living for a longer period of time, there may also be a stasis in idea generation.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-9\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">For the listener, you\u2019ve already mentioned wearables. What advice would you give to listeners who want to incorporate current longevity science insights into their daily lives?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-9\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Bear in mind, Andrew \u2014 and bear in mind, every listener \u2014 I am a generalist fund manager based in London with a liberal arts background, and therefore anything I say should not be treated as medical advice.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Were I to give advice, one superb, superb book which I read a while ago \u2014 which we did profile in one of our blogs \u2014 is called <em>Outlive<\/em> by a Canadian doctor called Dr. Peter Attia. And I think that book is well worth a read. What he asserts in that book, and I would concur with this, is that if you want to lead a longer and healthier life, then it is a combination of having good physical and mental health. In other words: exercise regularly, sleep well, make sure you surround yourself with interesting people \u2014 companionship is really good \u2014 make sure you\u2019re intellectually stimulated, and try and lead a good life. It ought not to be that complicated.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">But I think again, and to reference back to your question about ethics, there is this point that, in some ways, even doing an event like this, we are preaching to the converted. Many of your listeners, I imagine, will already be doing things like this \u2014 and they\u2019ll also have the disposable income to do this. The challenge is for less well-educated and poorer people to actually really embrace this approach of trying to make more preemptive lifestyle choices.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-10\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Thinking of the end of this decade, in five years\u2019 time, what development in longevity science do you get most excited by, Alex?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-10\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">I think, bigger picture, Andrew, where we are today is still \u2014 to use the American expression \u2014 in very early innings, and we are only really seeing AI at the training phase at the moment, rather than the influencing phase.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">And if we believe, if we\u2019re of the view, that AI can unlock great insights by applying knowledge to large sets of data, then the ability to come up with better healthcare solutions should only increase exponentially. I think, as we\u2019ve touched on on a couple of occasions, this idea of moving over time \u2014 and I\u2019d be reluctant to put a very specific timeline on it \u2014 toward more personalized, individualized medicine. The phrase <em>mass customization<\/em> springs to mind \u2014 that, I think, is what gets me really excited.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-11\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">A fantastic discussion once again, Alex. Thank you very much. How can individuals stay informed about credible advances in longevity research?&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-11\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Needless to say \u2014 and with the bias, of course, that this is just one source of information \u2014 clearly, this is one of the many future trends we seek to write about and uncover at Heptagon Capital. We discuss it regularly in our weekly blog and in thematic notes, such as the one we\u2019ve just been discussing. Above and beyond that, there\u2019s no shortage of information sources.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">I referenced one publication earlier on, and I think, as ever, the sort of caveat exists that it\u2019s not about the quantity of information that\u2019s available \u2014 it\u2019s about the quality. But really, again, if every listener is to take one thing away from this call, then it\u2019s really about this idea of trying to move the paradigm away from reaction toward preemption. Some of that\u2019s in your own hands; some of that will be enabled by technology.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-12\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Alex Gunz, Portfolio Manager at Heptagon Capital in London, thank you very much once again for joining me today.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-alex-gunz-nbsp-12\"><strong>Alex Gunz<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Thank you.&nbsp;<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-andrew-wilkinson-nbsp-13\"><strong>Andrew Wilkinson<\/strong>&nbsp;<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">And if you enjoyed today\u2019s episode, please don\u2019t forget \u2014 subscribe wherever you download your podcasts from. Bye for now.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>From CRISPR breakthroughs to AI-powered drug discovery, longevity science is moving from myth to marketplace. Host Andrew Wilkinson sits down with Alex Gunz, Portfolio Manager at Heptagon Capital, to explore how innovations in genomics, stem cells, and personalized medicine could redefine healthcare \u2014 and reshape the investment landscape. Discover why the race to extend lifespan may also unlock new long-term returns.<\/p>\n","protected":false},"author":111,"featured_media":231642,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[10842,13857],"tags":[20593,20591,20388,20590,1119,2059,20589,20595,20389,15769,20594,16205,20592],"contributors-categories":[13720,13576],"class_list":["post-231640","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ibkr-podcasts","category-podcasts","tag-aging-research","tag-ai-in-medicine","tag-alex-gunz","tag-biotech-investing","tag-crispr","tag-genomics","tag-healthcare-innovation","tag-healthspan","tag-heptagon-capital","tag-ibkr-podcasts","tag-lifespan","tag-longevity","tag-personalized-medicine","contributors-categories-heptagon-capital","contributors-categories-interactive-brokers"],"pp_statuses_selecting_workflow":false,"pp_workflow_action":"current","pp_status_selection":"publish","acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.9 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Is the Fountain of Youth Finally Open for Business?<\/title>\n<meta name=\"description\" content=\"From CRISPR breakthroughs to AI-powered drug discovery, longevity science is moving from myth to marketplace. Host Andrew Wilkinson sits down with Alex...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interactivebrokers.com\/campus\/wp-json\/wp\/v2\/posts\/231640\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is the Fountain of Youth Finally Open for Business? | IBKR Campus US\" \/>\n<meta property=\"og:description\" content=\"From CRISPR breakthroughs to AI-powered drug discovery, longevity science is moving from myth to marketplace. Host Andrew Wilkinson sits down with Alex Gunz, Portfolio Manager at Heptagon Capital, to explore how innovations in genomics, stem cells, and personalized medicine could redefine healthcare \u2014 and reshape the investment landscape. Discover why the race to extend lifespan may also unlock new long-term returns.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interactivebrokers.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/\" \/>\n<meta property=\"og:site_name\" content=\"IBKR Campus US\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-02T16:22:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-02T16:29:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/10\/pod20251001heptagon_coverimage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"563\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Andrew Wilkinson\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Andrew Wilkinson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\n\t    \"@context\": \"https:\\\/\\\/schema.org\",\n\t    \"@graph\": [\n\t        {\n\t            \"@type\": \"NewsArticle\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/#article\",\n\t            \"isPartOf\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/\"\n\t            },\n\t            \"author\": {\n\t                \"name\": \"Andrew Wilkinson\",\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/person\\\/d9f9f59fce942ef53aba42e7ff844803\"\n\t            },\n\t            \"headline\": \"Is the Fountain of Youth Finally Open for Business?\",\n\t            \"datePublished\": \"2025-10-02T16:22:15+00:00\",\n\t            \"dateModified\": \"2025-10-02T16:29:13+00:00\",\n\t            \"mainEntityOfPage\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/\"\n\t            },\n\t            \"wordCount\": 3281,\n\t            \"commentCount\": 1,\n\t            \"publisher\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#organization\"\n\t            },\n\t            \"image\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/#primaryimage\"\n\t            },\n\t            \"thumbnailUrl\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/10\\\/pod20251001heptagon_coverimage.jpg\",\n\t            \"keywords\": [\n\t                \"aging research\",\n\t                \"AI in medicine\",\n\t                \"Alex Gunz\",\n\t                \"biotech investing\",\n\t                \"Crispr\",\n\t                \"genomics\",\n\t                \"healthcare innovation\",\n\t                \"healthspan\",\n\t                \"Heptagon Capital\",\n\t                \"IBKR Podcasts\",\n\t                \"lifespan\",\n\t                \"Longevity\",\n\t                \"personalized medicine\"\n\t            ],\n\t            \"articleSection\": [\n\t                \"IBKR Podcasts\",\n\t                \"Podcasts\"\n\t            ],\n\t            \"inLanguage\": \"en-US\",\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"CommentAction\",\n\t                    \"name\": \"Comment\",\n\t                    \"target\": [\n\t                        \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/#respond\"\n\t                    ]\n\t                }\n\t            ]\n\t        },\n\t        {\n\t            \"@type\": \"WebPage\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/\",\n\t            \"url\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/\",\n\t            \"name\": \"Is the Fountain of Youth Finally Open for Business? | IBKR Campus US\",\n\t            \"isPartOf\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#website\"\n\t            },\n\t            \"primaryImageOfPage\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/#primaryimage\"\n\t            },\n\t            \"image\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/#primaryimage\"\n\t            },\n\t            \"thumbnailUrl\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/10\\\/pod20251001heptagon_coverimage.jpg\",\n\t            \"datePublished\": \"2025-10-02T16:22:15+00:00\",\n\t            \"dateModified\": \"2025-10-02T16:29:13+00:00\",\n\t            \"description\": \"From CRISPR breakthroughs to AI-powered drug discovery, longevity science is moving from myth to marketplace. Host Andrew Wilkinson sits down with Alex Gunz, Portfolio Manager at Heptagon Capital, to explore how innovations in genomics, stem cells, and personalized medicine could redefine healthcare \u2014 and reshape the investment landscape. Discover why the race to extend lifespan may also unlock new long-term returns.\",\n\t            \"inLanguage\": \"en-US\",\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"ReadAction\",\n\t                    \"target\": [\n\t                        \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/\"\n\t                    ]\n\t                }\n\t            ]\n\t        },\n\t        {\n\t            \"@type\": \"ImageObject\",\n\t            \"inLanguage\": \"en-US\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/podcasts\\\/ibkr-podcasts\\\/is-the-fountain-of-youth-finally-open-for-business\\\/#primaryimage\",\n\t            \"url\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/10\\\/pod20251001heptagon_coverimage.jpg\",\n\t            \"contentUrl\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/10\\\/pod20251001heptagon_coverimage.jpg\",\n\t            \"width\": 1000,\n\t            \"height\": 563\n\t        },\n\t        {\n\t            \"@type\": \"WebSite\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#website\",\n\t            \"url\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/\",\n\t            \"name\": \"IBKR Campus US\",\n\t            \"description\": \"Financial Education from Interactive Brokers\",\n\t            \"publisher\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#organization\"\n\t            },\n\t            \"potentialAction\": [\n\t                {\n\t                    \"@type\": \"SearchAction\",\n\t                    \"target\": {\n\t                        \"@type\": \"EntryPoint\",\n\t                        \"urlTemplate\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/?s={search_term_string}\"\n\t                    },\n\t                    \"query-input\": {\n\t                        \"@type\": \"PropertyValueSpecification\",\n\t                        \"valueRequired\": true,\n\t                        \"valueName\": \"search_term_string\"\n\t                    }\n\t                }\n\t            ],\n\t            \"inLanguage\": \"en-US\"\n\t        },\n\t        {\n\t            \"@type\": \"Organization\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#organization\",\n\t            \"name\": \"Interactive Brokers\",\n\t            \"alternateName\": \"IBKR\",\n\t            \"url\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/\",\n\t            \"logo\": {\n\t                \"@type\": \"ImageObject\",\n\t                \"inLanguage\": \"en-US\",\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/logo\\\/image\\\/\",\n\t                \"url\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2024\\\/05\\\/ibkr-campus-logo.jpg\",\n\t                \"contentUrl\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2024\\\/05\\\/ibkr-campus-logo.jpg\",\n\t                \"width\": 669,\n\t                \"height\": 669,\n\t                \"caption\": \"Interactive Brokers\"\n\t            },\n\t            \"image\": {\n\t                \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/logo\\\/image\\\/\"\n\t            },\n\t            \"publishingPrinciples\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/about-ibkr-campus\\\/\",\n\t            \"ethicsPolicy\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/cyber-security-notice\\\/\"\n\t        },\n\t        {\n\t            \"@type\": \"Person\",\n\t            \"@id\": \"https:\\\/\\\/ibkrcampus.com\\\/campus\\\/#\\\/schema\\\/person\\\/d9f9f59fce942ef53aba42e7ff844803\",\n\t            \"name\": \"Andrew Wilkinson\",\n\t            \"description\": \"Andrew Wilkinson is director of IBKR\u2019s trading education team and has been with the company since 2007. Before joining Interactive Brokers, Andrew began his career trading cash, interest rate products and derivative products in London before coming to the United States where he took his masters degree in Finance. He continued his career as a financial writer and commentator for publishers in London and the US. Andrew presents webinars and podcasts with contacts across the financial industry and helps educate investors via IBKR\u2019s Traders\u2019 Academy within the IBKR Campus.\",\n\t            \"url\": \"https:\\\/\\\/www.interactivebrokers.com\\\/campus\\\/author\\\/andrew-wilkinson\\\/\"\n\t        }\n\t    ]\n\t}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Is the Fountain of Youth Finally Open for Business?","description":"From CRISPR breakthroughs to AI-powered drug discovery, longevity science is moving from myth to marketplace. Host Andrew Wilkinson sits down with Alex...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interactivebrokers.com\/campus\/wp-json\/wp\/v2\/posts\/231640\/","og_locale":"en_US","og_type":"article","og_title":"Is the Fountain of Youth Finally Open for Business? | IBKR Campus US","og_description":"From CRISPR breakthroughs to AI-powered drug discovery, longevity science is moving from myth to marketplace. Host Andrew Wilkinson sits down with Alex Gunz, Portfolio Manager at Heptagon Capital, to explore how innovations in genomics, stem cells, and personalized medicine could redefine healthcare \u2014 and reshape the investment landscape. Discover why the race to extend lifespan may also unlock new long-term returns.","og_url":"https:\/\/www.interactivebrokers.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/","og_site_name":"IBKR Campus US","article_published_time":"2025-10-02T16:22:15+00:00","article_modified_time":"2025-10-02T16:29:13+00:00","og_image":[{"width":1000,"height":563,"url":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/10\/pod20251001heptagon_coverimage.jpg","type":"image\/jpeg"}],"author":"Andrew Wilkinson","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Andrew Wilkinson","Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/#article","isPartOf":{"@id":"https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/"},"author":{"name":"Andrew Wilkinson","@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/person\/d9f9f59fce942ef53aba42e7ff844803"},"headline":"Is the Fountain of Youth Finally Open for Business?","datePublished":"2025-10-02T16:22:15+00:00","dateModified":"2025-10-02T16:29:13+00:00","mainEntityOfPage":{"@id":"https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/"},"wordCount":3281,"commentCount":1,"publisher":{"@id":"https:\/\/ibkrcampus.com\/campus\/#organization"},"image":{"@id":"https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/10\/pod20251001heptagon_coverimage.jpg","keywords":["aging research","AI in medicine","Alex Gunz","biotech investing","Crispr","genomics","healthcare innovation","healthspan","Heptagon Capital","IBKR Podcasts","lifespan","Longevity","personalized medicine"],"articleSection":["IBKR Podcasts","Podcasts"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/","url":"https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/","name":"Is the Fountain of Youth Finally Open for Business? | IBKR Campus US","isPartOf":{"@id":"https:\/\/ibkrcampus.com\/campus\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/#primaryimage"},"image":{"@id":"https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/10\/pod20251001heptagon_coverimage.jpg","datePublished":"2025-10-02T16:22:15+00:00","dateModified":"2025-10-02T16:29:13+00:00","description":"From CRISPR breakthroughs to AI-powered drug discovery, longevity science is moving from myth to marketplace. Host Andrew Wilkinson sits down with Alex Gunz, Portfolio Manager at Heptagon Capital, to explore how innovations in genomics, stem cells, and personalized medicine could redefine healthcare \u2014 and reshape the investment landscape. Discover why the race to extend lifespan may also unlock new long-term returns.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibkrcampus.com\/campus\/podcasts\/ibkr-podcasts\/is-the-fountain-of-youth-finally-open-for-business\/#primaryimage","url":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/10\/pod20251001heptagon_coverimage.jpg","contentUrl":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/10\/pod20251001heptagon_coverimage.jpg","width":1000,"height":563},{"@type":"WebSite","@id":"https:\/\/ibkrcampus.com\/campus\/#website","url":"https:\/\/ibkrcampus.com\/campus\/","name":"IBKR Campus US","description":"Financial Education from Interactive Brokers","publisher":{"@id":"https:\/\/ibkrcampus.com\/campus\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibkrcampus.com\/campus\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ibkrcampus.com\/campus\/#organization","name":"Interactive Brokers","alternateName":"IBKR","url":"https:\/\/ibkrcampus.com\/campus\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/logo\/image\/","url":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2024\/05\/ibkr-campus-logo.jpg","contentUrl":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2024\/05\/ibkr-campus-logo.jpg","width":669,"height":669,"caption":"Interactive Brokers"},"image":{"@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/logo\/image\/"},"publishingPrinciples":"https:\/\/www.interactivebrokers.com\/campus\/about-ibkr-campus\/","ethicsPolicy":"https:\/\/www.interactivebrokers.com\/campus\/cyber-security-notice\/"},{"@type":"Person","@id":"https:\/\/ibkrcampus.com\/campus\/#\/schema\/person\/d9f9f59fce942ef53aba42e7ff844803","name":"Andrew Wilkinson","description":"Andrew Wilkinson is director of IBKR\u2019s trading education team and has been with the company since 2007. Before joining Interactive Brokers, Andrew began his career trading cash, interest rate products and derivative products in London before coming to the United States where he took his masters degree in Finance. He continued his career as a financial writer and commentator for publishers in London and the US. Andrew presents webinars and podcasts with contacts across the financial industry and helps educate investors via IBKR\u2019s Traders\u2019 Academy within the IBKR Campus.","url":"https:\/\/www.interactivebrokers.com\/campus\/author\/andrew-wilkinson\/"}]}},"jetpack_featured_media_url":"https:\/\/www.interactivebrokers.com\/campus\/wp-content\/uploads\/sites\/2\/2025\/10\/pod20251001heptagon_coverimage.jpg","_links":{"self":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/posts\/231640","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/users\/111"}],"replies":[{"embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/comments?post=231640"}],"version-history":[{"count":0,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/posts\/231640\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/media\/231642"}],"wp:attachment":[{"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/media?parent=231640"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/categories?post=231640"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/tags?post=231640"},{"taxonomy":"contributors-categories","embeddable":true,"href":"https:\/\/ibkrcampus.com\/campus\/wp-json\/wp\/v2\/contributors-categories?post=231640"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}